TNGX
Tango Therapeutics Inc
NASDAQ: TNGX · HEALTHCARE · BIOTECHNOLOGY
$20.98
-2.96% today
Updated 2026-05-01
Market cap
$3.18B
P/E ratio
—
P/S ratio
51.01x
EPS (TTM)
$-0.87
Dividend yield
—
52W range
$1 – $28
Volume
3.5M
Tango Therapeutics Inc (TNGX) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | $24.65M | $7.66M | $37.04M | $24.86M | $36.53M | $42.07M | $62.38M |
| Revenue growth (YoY) | — | -68.9% | +383.8% | -32.9% | +46.9% | +15.2% | +48.3% |
| Cost of revenue | $32.27M | $1.63M | $1.97M | $4.03M | $115.20M | $2.50M | $2.28M |
| Gross profit | $-7.63M | $6.03M | $37.04M | $24.86M | $36.53M | $42.07M | $60.10M |
| Gross margin | -30.9% | 78.8% | 100.0% | 100.0% | 100.0% | 100.0% | 96.3% |
| R&D | $32.27M | $49.99M | $77.64M | $105.91M | $115.20M | $143.92M | $132.16M |
| SG&A | $7.54M | $9.87M | $17.60M | $30.02M | $35.50M | $43.75M | $41.51M |
| Operating income | $-15.16M | $-52.20M | $-58.19M | $-111.07M | $-114.17M | $-145.59M | $-111.29M |
| Operating margin | -61.5% | -681.8% | -157.1% | -446.8% | -312.6% | -346.1% | -178.4% |
| EBITDA | $-14.52M | $-50.35M | $-57.29M | $-109.46M | $-111.76M | $-143.10M | $-109.01M |
| EBITDA margin | -58.9% | -657.6% | -154.7% | -440.3% | -306.0% | -340.1% | -174.7% |
| EBIT | $-15.16M | $-51.97M | $-58.19M | $-111.07M | $-114.17M | $-145.59M | $-111.29M |
| Interest expense | $0.00 | $0.00 | $1.14M | $2.95M | — | — | — |
| Income tax | — | — | — | — | — | — | — |
| Effective tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | $-14.10M | $-51.97M | $-58.23M | $-108.18M | $-101.74M | $-130.30M | $-101.59M |
| Net income growth (YoY) | — | -268.7% | -12.1% | -85.8% | +5.9% | -28.1% | +22.0% |
| Profit margin | -57.2% | -678.8% | -157.2% | -435.1% | -278.5% | -309.7% | -162.9% |